cytimmune-logo

Rockville-based CytImmune Sciences Inc. has raised $400,000 from the Maryland Venture Fund, Montgomery County and an unnamed venture investor to push Aurimune — a drug that pairs a decades-old tumor-fighting agent with gold nanoparticles — into phase 2 trials.

The Maryland Venture Fund led the round with $200,000, with another $100,000 coming from the Montgomery County Department of Economic Development and the unidentified investor.